First line and salvage therapy with total therapy 3-based treatment for multiple myeloma--An extended single center experience

Eli Muchtar; Ron Ram; Pia Raanani; Moshe Yeshurun; Nino Oniashvili; Ofer Shpilberg; Hila Magen

doi:10.1016/j.leukres.2014.06.024

First line and salvage therapy with total therapy 3-based treatment for multiple myeloma--An extended single center experience

Eli Muchtar, Ron Ram, Pia Raanani, Moshe Yeshurun, Nino Oniashvili, Ofer Shpilberg, Hila Magen

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Total therapy 3 is an intensified protocol for multiple myeloma (MM). The "real life" outcomes of this protocol were seldom reported. Data was obtained for 81 patients (newly diagnosed, n=. 49; progressive MM, n=. 32), most of which had high-risk parameters. Overall response rate following (V)DT-PACE was 96% and 75% for the newly diagnosed and progressive groups, respectively. Median progression-free survival was 42.5 and 9 months, respectively. The 2-year overall survival was 88% and 40%, respectively. Treatment with (V)DT-PACE achieves high response rate among patients with high-risk disease, which can be translated into long-term remission only for newly diagnosed patients.

Original language	English
Pages (from-to)	1401-1406
Number of pages	6
Journal	Leukemia Research
Volume	38
Issue number	12
DOIs	https://doi.org/10.1016/j.leukres.2014.06.024
State	Published - 1 Dec 2014
Externally published	Yes

Keywords

(V)DT-PACE
Bone disease
High dose therapy
High risk
Multiple myeloma
Total therapy

Access to Document

10.1016/j.leukres.2014.06.024

Cite this

@article{270f2929bd1e4ba9b21f251d983aa944,

title = "First line and salvage therapy with total therapy 3-based treatment for multiple myeloma--An extended single center experience",

abstract = "Total therapy 3 is an intensified protocol for multiple myeloma (MM). The {"}real life{"} outcomes of this protocol were seldom reported. Data was obtained for 81 patients (newly diagnosed, n=. 49; progressive MM, n=. 32), most of which had high-risk parameters. Overall response rate following (V)DT-PACE was 96% and 75% for the newly diagnosed and progressive groups, respectively. Median progression-free survival was 42.5 and 9 months, respectively. The 2-year overall survival was 88% and 40%, respectively. Treatment with (V)DT-PACE achieves high response rate among patients with high-risk disease, which can be translated into long-term remission only for newly diagnosed patients.",

keywords = "(V)DT-PACE, Bone disease, High dose therapy, High risk, Multiple myeloma, Total therapy",

author = "Eli Muchtar and Ron Ram and Pia Raanani and Moshe Yeshurun and Nino Oniashvili and Ofer Shpilberg and Hila Magen",

note = "Publisher Copyright: {\textcopyright} 2014 Elsevier Ltd.",

year = "2014",

month = dec,

day = "1",

doi = "10.1016/j.leukres.2014.06.024",

language = "אנגלית",

volume = "38",

pages = "1401--1406",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "12",

}

TY - JOUR

T1 - First line and salvage therapy with total therapy 3-based treatment for multiple myeloma--An extended single center experience

AU - Muchtar, Eli

AU - Ram, Ron

AU - Raanani, Pia

AU - Yeshurun, Moshe

AU - Oniashvili, Nino

AU - Shpilberg, Ofer

AU - Magen, Hila

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Total therapy 3 is an intensified protocol for multiple myeloma (MM). The "real life" outcomes of this protocol were seldom reported. Data was obtained for 81 patients (newly diagnosed, n=. 49; progressive MM, n=. 32), most of which had high-risk parameters. Overall response rate following (V)DT-PACE was 96% and 75% for the newly diagnosed and progressive groups, respectively. Median progression-free survival was 42.5 and 9 months, respectively. The 2-year overall survival was 88% and 40%, respectively. Treatment with (V)DT-PACE achieves high response rate among patients with high-risk disease, which can be translated into long-term remission only for newly diagnosed patients.

AB - Total therapy 3 is an intensified protocol for multiple myeloma (MM). The "real life" outcomes of this protocol were seldom reported. Data was obtained for 81 patients (newly diagnosed, n=. 49; progressive MM, n=. 32), most of which had high-risk parameters. Overall response rate following (V)DT-PACE was 96% and 75% for the newly diagnosed and progressive groups, respectively. Median progression-free survival was 42.5 and 9 months, respectively. The 2-year overall survival was 88% and 40%, respectively. Treatment with (V)DT-PACE achieves high response rate among patients with high-risk disease, which can be translated into long-term remission only for newly diagnosed patients.

KW - (V)DT-PACE

KW - Bone disease

KW - High dose therapy

KW - High risk

KW - Multiple myeloma

KW - Total therapy

UR - http://www.scopus.com/inward/record.url?scp=84916207898&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2014.06.024

DO - 10.1016/j.leukres.2014.06.024

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 25060304

AN - SCOPUS:84916207898

SN - 0145-2126

VL - 38

SP - 1401

EP - 1406

JO - Leukemia Research

JF - Leukemia Research

IS - 12

ER -

First line and salvage therapy with total therapy 3-based treatment for multiple myeloma--An extended single center experience

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this